ciprofloxacin has been researched along with Obesity, Morbid in 4 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofloxacin is a fluoroquinolone used for empirical and targeted therapy of a wide range of infections." | 1.72 | Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. ( Brüggemann, RJM; Knibbe, CAJ; Krekels, EHJ; Smit, C; van der Linden, PD; Van Dongen, EPA; van Rhee, KP; Wasmann, RE; Wiezer, R, 2022) |
| "In the absence of clinical studies, the ability to project the direction and the magnitude of changes in bioavailability of drug therapy, using evidence-based mechanistic pharmacokinetic in silico models would be of significant value in guiding prescribers to make the necessary adjustments to dosage regimens for an increasing population of patients who are undergoing bariatric surgery." | 1.38 | A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. ( Ammori, BJ; Ashcroft, DM; Darwich, AS; Jamei, M; Pade, D; Rostami-Hodjegan, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Rhee, KP | 1 |
| Smit, C | 1 |
| Wasmann, RE | 1 |
| van der Linden, PD | 1 |
| Wiezer, R | 1 |
| Van Dongen, EPA | 1 |
| Krekels, EHJ | 1 |
| Brüggemann, RJM | 1 |
| Knibbe, CAJ | 1 |
| El-Nashar, SA | 1 |
| Diehl, CL | 1 |
| Swanson, CL | 1 |
| Thompson, RL | 1 |
| Cliby, WA | 1 |
| Famuyide, AO | 1 |
| Stanhope, CR | 1 |
| Darwich, AS | 1 |
| Pade, D | 1 |
| Ammori, BJ | 1 |
| Jamei, M | 1 |
| Ashcroft, DM | 1 |
| Rostami-Hodjegan, A | 1 |
| Caldwell, JB | 1 |
| Nilsen, AK | 1 |
4 other studies available for ciprofloxacin and Obesity, Morbid
| Article | Year |
|---|---|
Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study.
Topics: Administration, Intravenous; Ciprofloxacin; Humans; Infusions, Intravenous; Obesity, Morbid; Prospec | 2022 |
Extended antibiotic prophylaxis for prevention of surgical-site infections in morbidly obese women who undergo combined hysterectomy and medically indicated panniculectomy: a cohort study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents | 2010 |
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Topics: Administration, Oral; Bariatric Surgery; Biological Availability; Chemistry, Pharmaceutical; Ciprofl | 2012 |
Intravenous ciprofloxacin dosing in a morbidly obese patient.
Topics: Adipose Tissue; Bacterial Infections; Body Weight; Cellulitis; Ciprofloxacin; Humans; Infusions, Int | 1994 |